Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial
-
- Mok
- 作成者
収録刊行物
-
- J Clin Oncol
-
J Clin Oncol 32 5s-, 2014
